类风湿关节炎。甲氨蝶呤治疗失败后三联疗法还是依那西普？
Rheumatoid arthritis. Triple therapy or etanercept after methotrexate failure in RA?
机构信息
Unit for Clinical Therapy Research, Inflammatory Diseases, The Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
出版信息
Nat Rev Rheumatol. 2013 Sep;9(9):510-2. doi: 10.1038/nrrheum.2013.118. Epub 2013 Jul 30.
PMID:23897440
Abstract
Since the 1990s, patients with rheumatoid arthritis have been treated with at least one DMARD. Methotrexate, which is usually the first-line treatment, elicits good or even excellent clinical results in 20–30% of patients—but in most patients it does not. Thus, an important question is what to do after methotrexate failure.
摘要
自 20 世纪 90 年代以来，类风湿关节炎患者至少接受过一种 DMARD 治疗。甲氨蝶呤通常是一线治疗药物，在 20%至 30%的患者中疗效良好甚至极佳，但在大多数患者中并非如此。因此，一个重要的问题是在甲氨蝶呤治疗失败后该怎么办。
Zotero 插件